Aim. To identify new minimally invasive serum markers of fibrotic liver changes in patients with MASLD and compare them with well-known fibrosis diagnostic indices. Conclusions. Comparison of the diagnostic value of biological markers obtained in our study with well-known fibrosis scores showed that TNFα/IL-10, NOMA-IR, and α1-acid glycopeptide content are more sensitive and specific. New possible biomarkers for predicting the development of liver fibrosis in patients with MASLD were obtained. A largest cogort and additional studies are needed to validate the proposed biomarkers panel.